Thyrocare Technologies Ltd, Gujarat State Fertilizers & Chemicals Ltd, Apollo Tyres Ltd, Sheela Foam Ltd are among the other stocks to see a surge in volumes on BSE today, 01 January 2021.

Pfizer Ltd notched up volume of 25610 shares by 10:47 IST on BSE, a 3.41 fold spurt over two-week average daily volume of 7518 shares. The stock rose 3.54% to Rs.5,288.55. Volumes stood at 1948 shares in the last session.

Thyrocare Technologies Ltd witnessed volume of 17383 shares by 10:47 IST on BSE, a 2.23 times surge over two-week average daily volume of 7794 shares. The stock increased 2.73% to Rs.938.35. Volumes stood at 2250 shares in the last session.

Gujarat State Fertilizers & Chemicals Ltd witnessed volume of 2.13 lakh shares by 10:47 IST on BSE, a 1.9 times surge over two-week average daily volume of 1.12 lakh shares. The stock increased 5.87% to Rs.76.60. Volumes stood at 67791 shares in the last session.

Apollo Tyres Ltd notched up volume of 8.84 lakh shares by 10:47 IST on BSE, a 1.88 fold spurt over two-week average daily volume of 4.71 lakh shares. The stock slipped 0.20% to Rs.177.70. Volumes stood at 4.72 lakh shares in the last session.

Sheela Foam Ltd saw volume of 1162 shares by 10:47 IST on BSE, a 1.72 fold spurt over two-week average daily volume of 674 shares. The stock increased 3.56% to Rs.1,802.75. Volumes stood at 158 shares in the last session.

Powered by Capital Market - Live News

As per media reports, Pfizer Inc has sought an emergency use authorisation for its messenger RNA vaccine from the Drug Controller General of India V.G. Somani. The company is seeking permission to import the vaccine for sale and distribution in the country as well as skip a phase 3 bridging study, the reports added.

Pfizer Inc's vaccine had reportedly shown robust efficacy data against covid-19 in a recently concluded US trial.

Last week, the UK Medicines & Healthcare Products Regulatory Agency (MHRA) became the first regulator to grant a temporary authorisation for use of the Covid-19 mRNA vaccine, which Pfizer has co-developed with German company BioNTech.

Pfizer is a research-based global biopharmaceutical company which is engaged in the discovery, development and manufacture of healthcare products.

The drug maker's net profit dropped 14.83% to Rs 131.37 crore on 4.99% increase in revenue from operations to Rs 595.41 crore in Q2 September 2020 over Q2 September 2019.

Powered by Capital Market - Live News

Phoenix Mills Ltd, Sterling & Wilson Solar Ltd, CSB Bank Ltd, Bharti Infratel Ltd are among the other stocks to see a surge in volumes on NSE today, 02 December 2020.

Pfizer Ltd registered volume of 8.01 lakh shares by 14:14 IST on NSE, a 6.83 fold spurt over two-week average daily volume of 1.17 lakh shares. The stock rose 3.47% to Rs.5,285.00. Volumes stood at 40414 shares in the last session.

Phoenix Mills Ltd recorded volume of 20.87 lakh shares by 14:14 IST on NSE, a 6.74 times surge over two-week average daily volume of 3.09 lakh shares. The stock gained 11.81% to Rs.770.65. Volumes stood at 2.33 lakh shares in the last session.

Sterling & Wilson Solar Ltd recorded volume of 14.88 lakh shares by 14:14 IST on NSE, a 5.59 times surge over two-week average daily volume of 2.66 lakh shares. The stock gained 7.70% to Rs.244.75. Volumes stood at 4.47 lakh shares in the last session.

CSB Bank Ltd registered volume of 7.5 lakh shares by 14:14 IST on NSE, a 5.32 fold spurt over two-week average daily volume of 1.41 lakh shares. The stock slipped 5.76% to Rs.233.25. Volumes stood at 1.89 lakh shares in the last session.

Bharti Infratel Ltd notched up volume of 1223.88 lakh shares by 14:14 IST on NSE, a 5.31 fold spurt over two-week average daily volume of 230.42 lakh shares. The stock rose 3.38% to Rs.223.30. Volumes stood at 175.77 lakh shares in the last session.

Powered by Capital Market - Live News

The scrip jumped 19.46% to hit the day's high at Rs 5875 in early trade. The counter witnessed volume of 72,122 shares on the BSE, a 23.42 times surge over two-week average daily volume of 3,079 shares. On the NSE, the counter witnessed volume of 13,95,616 shares, a 24.37 times surge over three-month average daily volume of 57,265 shares.

Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on 8 November 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

The analysis evaluated 94 confirmed cases of COVID-19 in trial participants. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. As the study continues, the final vaccine efficacy percentage may vary.

The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

Dr. Albert Bourla, Pfizer Chairman and CEO, said: The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.

Pfizer and Germany's BioNTech are in a race with companies including AstraZeneca Plc, Moderna Inc. and dozens of other biopharmaceutical outfits and academic groups to come up with a safe and effective vaccine against Covid-19.

Pfizer is a research-based global biopharmaceutical company which is engaged in the discovery, development and manufacture of healthcare products.

The drug maker's net profit dropped 14.83% to Rs 131.37 crore on 4.99% increase in revenue from operations to Rs 595.41 crore in Q2 September 2020 over Q2 September 2019.

Powered by Capital Market - Live News